PAD2-Mediated Citrullination Contributes to Efficient Oligodendrocyte Differentiation and Myelination by Falcão, Ana Mendanha et al.
u n i ve r s i t y  o f  co pe n h ag e n  
Københavns Universitet
PAD2-Mediated Citrullination Contributes to Efficient Oligodendrocyte Differentiation
and Myelination
Falcão, Ana Mendanha; Meijer, Mandy; Scaglione, Antonella; Rinwa, Puneet; Agirre, Eneritz;
Liang, Jialiang; Larsen, Sara C; Heskol, Abeer; Frawley, Rebecca; Klingener, Michael; Varas-
Godoy, Manuel; Raposo, Alexandre A S F; Ernfors, Patrik; Castro, Diogo S; Nielsen, Michael
L.; Casaccia, Patrizia; Castelo-Branco, Gonçalo
Published in:
Cell Reports
DOI:
10.1016/j.celrep.2019.03.108
Publication date:
2019
Document version
Publisher's PDF, also known as Version of record
Document license:
CC BY
Citation for published version (APA):
Falcão, A. M., Meijer, M., Scaglione, A., Rinwa, P., Agirre, E., Liang, J., ... Castelo-Branco, G. (2019). PAD2-
Mediated Citrullination Contributes to Efficient Oligodendrocyte Differentiation and Myelination. Cell Reports,
27(4), 1090-1102.e10. https://doi.org/10.1016/j.celrep.2019.03.108
Download date: 03. Feb. 2020
ArticlePAD2-Mediated Citrullination Contributes to
Efficient Oligodendrocyte Differentiation and
MyelinationGraphical AbstractMyelinationDifferentiation
OPCs
(Oligodendrocyte 
Precursor Cells)
COPs/NFOLs
(Committed Oligodendrocyte
Precursors/ Newly Formed
Oligodendrocytes)
MOLs
(Mature 
Oligodendrocytes)
Padi2 
citcit cit
cit
cit
cit
cit
cit
CKB
PPIA
EEF1A1
WDR1
CNP
NME1
cit
ProliferationHighlightsd PAD2 is increased upon OL differentiation
d OL differentiation is facilitated by PAD2-mediated chromatin
remodeling in myelin genes
d PAD2 contributes to efficient myelination and motor and
cognitive functions
d Nuclear and myelin proteins interact and are citrullinated by
PAD2Falc~ao et al., 2019, Cell Reports 27, 1090–1102
April 23, 2019 ª 2019 The Authors.
https://doi.org/10.1016/j.celrep.2019.03.108Authors
Ana Mendanha Falc~ao, Mandy Meijer,
Antonella Scaglione, ...,
Michael L. Nielsen, Patrizia Casaccia,
Gonc¸alo Castelo-Branco
Correspondence
goncalo.castelo-branco@ki.se
In Brief
Falc~ao et al. demonstrate that PAD2-
mediated citrullination, the conversion of
peptidylarginine into peptidylcitrulline,
has two roles in oligodendrocyte cells. In
the nucleus, PAD2 acts as a chromatin
modifier contributing to efficient
oligodendrocyte precursor cell
differentiation, while in the cytoplasm
PAD2 is required for proper
oligodendrocyte myelination.
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Citrullination, the deimination of peptidylarginine res-
idues into peptidylcitrulline, has been implicated in
the etiology of several diseases. In multiple sclerosis,
citrullination is thought to be a major driver of pathol-
ogy through hypercitrullination and destabilization of
myelin. As such, inhibition of citrullination has been
suggested as a therapeutic strategy for MS. Here, in
contrast, we show that citrullination by peptidylargi-
nine deiminase 2 (PAD2) contributes to normal oligo-
dendrocyte differentiation, myelination, and motor
function. We identify several targets for PAD2,
including myelin and chromatin-related proteins,
implicating PAD2 in epigenomic regulation. Accord-
ingly, we observe that PAD2 inhibition and its knock-
down affect chromatin accessibility and prevent
the upregulation of oligodendrocyte differentiation
genes. Moreover, mice lacking PAD2 display motor
dysfunction and a decreased number of myelinated
axons in the corpus callosum. We conclude that
citrullination contributes to proper oligodendrocyte
lineage progression and myelination.
INTRODUCTION
The conversion of a peptidylarginine into a peptidylcitrulline can
introduce profound changes in the structure and function of the
modified protein. This posttranslational modification, also known
as protein citrullination or deimination, is calcium dependent and1090 Cell Reports 27, 1090–1102, April 23, 2019 ª 2019 The Authors
This is an open access article under the CC BY license (http://creativeis mediated by the family of enzymes called peptidylarginine
deiminases (Padis or PADs) (Wang and Wang, 2013). Five PAD
isozymes (PAD1, PAD2, PAD3, PAD4, and PAD6) have been
identified in mammals, and their expression patterns and func-
tion are tissue specific (Vossenaar et al., 2003). Citrullination
has been recently shown to play key roles inmultiple cellular pro-
cesses, such as inflammatory immune responses (Neeli et al.,
2008), apoptosis (Liu et al., 2006), and regulation of pluripotency
(Christophorou et al., 2014). In the central nervous system (CNS),
PAD2 is themost prevalent expressed PAD and occurs preferen-
tially in oligodendrocytes (OLs) and other glial cells (Zeisel et al.,
2015). OLs arise at postnatal stages from the differentiation of OL
precursor cells (OPCs), and their most prominent function is the
formation of the myelin sheath, an electrical insulating layer for
the axons, essential for proper neuronal communication and
thus CNS function (Bergles and Richardson, 2015).
PAD2 has been reported to heavily citrullinate myelin binding
protein (MBP), a fundamental myelin component. The ratio of cit-
rullinatedMBP (MBPcit) to total MBP (MBPtotal) is high in the first
4 years of life and similarly in multiple sclerosis (MS), a disease in
which demyelination occurs (Moscarello et al., 1994). Upon citrul-
lination, MBP arginine residues lack positive charges and thereby
have reduced interaction with negatively charged lipids. Conse-
quently, MBPcit does not form compact sheaths, and the myelin
remains immature or becomes unstable (Beniac et al., 2000). In
accordance, transgenic mice overexpressing PAD2 in OL cells
display myelin loss (Musse et al., 2008). In light of this, PADs, in
particular PAD2, have been thought to have a detrimental effect
inMS, and thus alleviation of symptoms can be achieved by inhib-
iting their actions (Caprariello et al., 2018). Indeed, treatment of an
MSmousemodel of experimental autoimmune encephalomyelitis
(EAE) with 2-chloroacetamidine (2-CA), a PAD2 and PAD4.
commons.org/licenses/by/4.0/).
Figure 1. Padi2 Expression Is Substantially Increased upon OL Differentiation
(A) Schematic representation of themethodology used for OPC in vitro cultures. P1–P4GFP+OPCs are dissociated frombrains of the transgenicmice line Pdgfra-
H2B-GFP and FACS-sorted to plates to expand in the presence of growth factors (GFs). GFs are removed to induce differentiation for 2 days.
(B) Comparative gene expression analysis of OPCs and 2 day differentiated OLs. Means ± SEM are shown, n = 3; *p < 0.05, two-tailed t test.
(C) Schematic representation of the methodology used to specifically isolate OPCs and juvenile and adult OLs from the postnatal (P1–P4), juvenile (P21), and adult
(P60) brains of the transgenicmice PdgfraCre;RCE:loxP (R26RCAG-boostedEGFP); GFP+ cells were depleted of theOPCmarkerCD140a to specifically isolateOLs.
(D) Comparative gene expression analysis of OPCs and juvenile and adult OLs. Means ± SEM are shown, n = 4; *p < 0.05, one-way non-parametric ANOVA.
(E) Western blot for PADI2 and MBP on the spinal cords of P1, P7, P14, P21, and adult wild-type mice. ACTIN signal is an internal loading control.
See also Figure S1.inhibitor, leads todisease attenuation (Moscarello et al., 2013). The
reduction of disease progression by 2-CA treatment was not spe-
cifically assigned to the lack of PAD activity in OL lineage cells
alone but to inhibition of all PAD-expressing cells, including im-
mune cells that play an essential role in disease development.
Interestingly, however, no changes in disease progression
were observed upon EAE induction in PAD2 KO mice (Raij-
makers et al., 2006). This could point to a possible compensation
of PAD2 functions by other PADs or to additional functions of
PAD2 in EAE disease progression. Although citrullination of
myelin might play an important role in MS, other proteins, such
as histone H3, have been found to be citrullinated in MS (Mastro-
nardi et al., 2006). Thus, the role of PAD2-mediated citrullination
inMSmight not be confined tomyelin. Furthermore, although the
effects of Padi2 overexpression in mature OLs have been char-
acterized, its absence in OL lineage cells has not been further
investigated, nor its physiological function in OL lineage cells
and its significance for myelin integrity maintenance.
RESULTS
Padi2 Expression Is Increased upon OL Differentiation
By analyzing our single-cell RNA sequencing (RNA-seq) data-
set of the OL lineage in the adult and juvenile mouse brain (Mar-ques et al., 2016), we identified Padi2 as the predominant Padi
expressed in OLs (Figure S1A). Interestingly, Padi2 expression
is found in OPCs, increases in committedOL precursors (COPs)
and newly formed OLs (NFOLs), and peaks at more mature
stages (Figure S1A). Surprisingly, we did not observe expres-
sion of Padi4, which has been previously suggested to be pre-
sent in myelin (Mastronardi et al., 2006; Wood et al., 2008). To
further investigate the pattern of expression of Padi2 during
early OL lineage progression, we cultured OPCs isolated from
postnatal day (P) 1 to P4 brains of the transgenic mouse line
Pdgfra-histone 2b (H2B)-GFP (Klinghoffer et al., 2002) in which
nuclear GFP expression is under the control of the endogenous
Pdgfra promoter locus. GFP+ OPCs were collected with fluo-
rescence-activated cell sorting (FACS) to plates and expanded
in media containing the growth factors (GFs) basic fibroblast
growth factor (bFGF) and platelet-derived growth factor
(PDGF)-AA and differentiated into OLs by removing the GFs
for 2 days (Figure 1A). Gene expression of the differentiation
markers Mbp and Sox10 was upregulated, and the progenitor
marker Pdgfra was reduced upon GF removal (Figure 1B). In
agreement with the single-cell RNA-seq data, Padi2 was ex-
pressed in OPCs, and it was greatly enhanced upon differenti-
ation (Figure 1B; Figure S1B, for the mouse oligodendroglia cell
line Oli-neu; Jung et al., 1995). To investigate Padi2 expressionCell Reports 27, 1090–1102, April 23, 2019 1091
Figure 2. PAD Inhibition and Padi2 Knockdown Hinders OPC Differentiation
(A) Immunocytochemistry for CNPase and cleaved Casp3 on 2 day differentiated Oli-neu upon 2 days treatment with DMSO or Cl-amidine 200 mM and quan-
tification of the percentage of cleaved Casp3+ cells out of total DAPI in all conditions. Scale bar, 20 mm.
(B) Comparative gene expression analysis of proliferating and undifferentiated (Und) Oli-neu cells and 2 day differentiatedOli-neu cells (Diff) treated with DMSO or
Cl-amidine 200 mM for 2 days. Means ± SEM are shown, n = 3; *p < 0.05, two-tailed t test.
(C) Gene expression analysis on proliferating rat primary OPCs treated with Cl-amidine 100 mM; dashed line represents control levels, normalized to 1. Means ±
SEM are shown, n = 3; *p < 0.05, one-sample t test.
(D) Comparative gene expression analysis onmouse primary undifferentiated (Und) and 2 day differentiated OLs (Diff) transfected with either scrambled siRNA or
Padi2 siRNA targeting exon 2. Means ± SEM are shown, n = 4; *p < 0.05, two-tailed t test; error bars represent SEM.
See also Figure S1.in the OL lineage in vivo, we isolated OPCs and OLs from the
brain of the transgenic mouse line Pdgfra-Cre-loxP-GFP
(Kang et al., 2010), in which all OL lineage cells express the
GFP reporter (Figure 1C). GFP+ OPCs were collected with
FACS from P1–P4 pups (all GFP+ cells are OPCs because
OLs are not formed yet), and GFP+ CD140a OLs were
collected with FACS from juvenile (P21) and adult (P60) mice
(at this stage, GFP+ cells comprise all OL progeny, including
CD140a+ OPCs). As a confirmation of the sorted populations,
we assessed the expression of Pdgfra and Mbp as markers
for OPCs and differentiated OLs, respectively (Figure 1D).
Padi2mRNA was substantially enriched in OLs from both juve-
nile and adult brains compared with postnatal OPCs (Fig-
ure 1D). At the protein level, and in agreement with our gene
expression data, we observed a continuous increase in PAD2
protein from P1 to adult in the spinal cord of wild-type mice,
concomitant with the increase in the OL marker MBP (Fig-
ure 1E). Thus, PAD2 is rapidly upregulated upon OPC differen-
tiation, suggesting a role of this citrullinating enzyme at this
stage of OL lineage progression.1092 Cell Reports 27, 1090–1102, April 23, 2019Reduction of PAD2 Activity Hinders OL Differentiation
In order to investigate whether the increased expression ofPadi2
upon OL differentiation has functional significance, we inhibited
PAD activity in mouse Oli-neu cells and rat primary OPCs using
Cl-amidine, a pan-inhibitor of PAD enzymes. The concentration
used of PAD inhibitor (200 mM) has been used in other studies
(Christophorou et al., 2014; Xiao et al., 2017) and had no effect
on cell death in Oli-neu cells, as assessed using cleaved
CASP3 immunostaining (Figure 2A). Strikingly, Oli-neu cell differ-
entiation was compromised in the presence of this inhibitor, as
observed by the reduction of cell branching typical of differenti-
ating OLs shown with CNPase immunostaining (Figure 2A). In
accordance, gene expression analysis on undifferentiated and
differentiated Oli-neu cells treated with Cl-amidine revealed a
striking impairment of OPC differentiation. The increase of
Mbp, Sox10, and Mog mRNA levels, crucial for proper OPC dif-
ferentiation, were no longer observed after Cl-amidine during
differentiation (Figure 2B). Interestingly, the expression of the
transcription factor (TF) Sox9, required for OL specification (Stolt
et al., 2003) and downregulated upon OPC differentiation
(Marques et al., 2016), was increased upon PAD inhibition (Fig-
ure 2B). Because Sox9 is highly expressed in astrocytes, we
further investigated if the upregulation of Sox9 drove OPCs
into astrocytes. We did not observe any upregulation of the as-
trocytic marker Gfap upon PAD inhibition, ruling out a possible
differentiation of OPCs into astrocytes instead of OLs (Fig-
ure S1D). Similar results on impairment of OPC differentiation
were obtained by treating Oli-neu with another PAD inhibitor,
2-CA (Figure S1C). Importantly, these effects were also
observed in rat OPC primary cultures, in which under differenti-
ating conditions, treatment with 50 or 100 mM Cl-amidine
impaired differentiation, as observed by the lowermRNA expres-
sion levels of the differentiation markers Mbp, Sox10, and Mog
(Figure 2C). In contrast to Oli-neu, Sox9 was reduced upon
PAD2 inhibition in rat OPC primary cultures (Figure 2C).
To investigate whether the effect of PAD inhibitors was due to
PAD2 inhibition, we specifically decreased Padi2mRNA levels in
mouse primary OPCs by transfecting cells with small interfering
RNA (siRNA) against Padi2 (targeting exon 2). Similar to PAD in-
hibition, the reduction of Padi2 expression led to decreases in
the mRNA levels of Sox10 and Mog and an increase in Sox9
without altering Gfap mRNA levels (Figures 2D and S1F). Mog,
Mbp, andSox10mRNA levels were also reduced inPadi2 knock-
down conditions after 2 days of differentiation (Figure 2D). Like-
wise, Padi2 knockdown in Oli-neu cells mimicked the effects of
PAD inhibition (Figure S1E). The results with inhibitors in Oli-
neu are stronger than in primary OPCs, most likely because
the inhibitors act in a quicker manner and irreversibly inhibit all
PAD2 present in Oli-neu cells, whereas Padi2 knockdown is
slower and not as effective in reducing PAD2 activity. Thus,
our findings indicate that PAD2 is dramatically increased at the
onset of OL differentiation, when it contributes to the transition
from an OPC state to an NFOL state.
OLs Are Transiently Reduced in the Spinal Cord of
Juvenile Mice upon Conditional Padi2 Knockout in the
OL Lineage
To investigate if the observed effects of PAD2 have an impact
on OL differentiation and myelin maintenance in vivo, we
generated a Padi2 conditional knockout (cKO) mouse line,
PdgfraCre;RCE:loxP;Padi2/, in which Padi2 is not present in
any cells derived from Pdgfra+ cells, which include the whole
OL lineage. We estimated the number of CC1+ cells per area at
P21, in the corpus callosum, anterior commissure, and dorsal
funiculus of the spinal cord. In accordance with our results in
Oli-neu and primary OPC cultures (Figure 2), we observed a
reduction in the number of CC1+ OLs in the spinal cord of
PAD2 cKO mice, compared with littermate controls (Figures 3A
and 3B). Nevertheless, we did not observe such an effect in
the brain (corpus callosum and anterior commissure) (Figure 3A).
Accordingly, we observed that Pdgfra, Mbp, and Mog mRNA
were unaltered in FACS cKO GFP+ cells from P21 brains (Fig-
ure S2C), indicating that the Padi2 cKO does not affect OL cell
number or transcription in the brain but rather has a more prom-
inent effect in OPC differentiation in posterior regions of the CNS.
To further address if the effect in the spinal cord is sustained in
adulthood, we estimated CC1+ cell densities in 4-month-old
mice. We did not observe any difference in the three regionsanalyzed (Figure 3A), suggesting that there is a recovery in the
number of generated CC1+ cells in adult stages in the spinal
cord.
We also generated an induciblePadi2 cKO (indKO)mouse line,
PdgfraCreERT;RCE:loxP;Padi2/, for which Padi2 could be ab-
lated from OPCs by tamoxifen treatment at early postnatal
stages (Figure 3C). Because we observed that PAD2 mainly
modulates the transition between OPCs and NFOLs in vitro (Fig-
ure 2), we depleted Padi2 specifically at the onset of OPC differ-
entiation by injecting mice with tamoxifen at P6 and collecting
the brains and spinal cord at P11 (Figure 3C). We observed a
slight effect of the number of OLs formed upon tamoxifen-
induced OPC Padi2 depletion, which nevertheless was not
statistically significant (p = 0.0828 for corpus callosum and p =
0.0567 for spinal cord; Figure 3D). Thus, our results with Padi2
constitutive ablation in OPC suggest that PAD2 facilitates the
generation of OLs in vivo in the spinal cord.
Padi2 KO Mice Display Impaired Motor and Cognitive
Functions and a Decrease in the Number of Myelinated
Axons
Given the transient decrease in OLs upon Padi2 cKO in the OL
lineage in the spinal cord and the targeting of myelin proteins
by PAD2, we investigated whether Padi2 cKO mice presented
a motorical phenotype. Interestingly, Padi2 cKO mice exhibited
impairment in motor coordination and balance as assessed by
decreased latency to fall in the rotarod test (Figure 4A). More-
over, we observed similar impairments in the full Padi2 KO
(Padi2 fKO), in which exon 1 of Padi2 is deleted in all cells (Raij-
makers et al., 2006). In addition, we found an increase in the
number of slips on the beam test in the Padi2 cKO mice,
strengthening the motor impairment phenotype (Figure 4B).
Interestingly, when testing the Padi2 cKO mice for cognitive
functions, these mice also performed worst in the novel object
recognition test, displaying a decrease in the discrimination
index that provides an indication of recognition memory
(Figure 4C).
To further investigate the mechanisms underlying the impact
of PAD2 on motor and cognitive functions, we analyzed the
myelin structure of the Padi2 fKO mice and respective controls
using electron microcopy (EM). We found a significant decrease
in the g-ratio of small-diameter axons and an increase in the
g-ratio of axons with 0.6–0.9 mm diameter (Figures 4D–4F).
Moreover, the percentage of myelinated axons in the corpus
callosum was decreased in Padi2 fKO mice compared with
controls (Figure 4G). As such, our results indicate that PAD2
plays a role initially for efficient OL differentiation in the spinal
cord and later on in myelination in the corpus callosum, which
is reflected in the motoric and cognitive defects occurring
upon its ablation.
PAD2 Is Present in Both the Nucleus and Cytoplasm in
OL Lineage Cells
To disclose the possible mechanisms of action underlying the
observed in vitro and in vivo effects, we further investigated the
cellular location of PAD2 in OL lineage cells. Despite that PAD4
is the only one displaying a nuclear localization signal (NLS),
PAD2 has recently been detected in the nuclei of mammaryCell Reports 27, 1090–1102, April 23, 2019 1093
Figure 3. Padi2 Knockout Mice Display a Transient Decrease in OPC Differentiation in the Spinal Cord
(A) CC1+ cells are presented as number of positive cells per area in the corpus callosum, anterior commissure, and spinal cord of PdgfraCre;RCE:loxP;Padi2+/+
and PdgfraCre;RCE:loxP;Padi2/ juvenile (P21) and adult mice. Means ± SEM are shown, n = 4 (P21) and n = 5 (adult); *p < 0.05, two-tailed t test.
(B) Representative images of the spinal cord dorsal funiculus of PdgfraCre;RCE:loxP;Padi2+/+ and PdgfraCre;RCE:loxP;Padi2/mice stained with CC1 antibody
and DAPI. Scale bar, 20 mm.
(C) Schematic representation of the strategy used to deplete Padi2 immediately before the peak of OPC differentiation: PdgfraCreERT;RCE:loxP;Padi2+/+ and
PdgfraCreERT;RCE:loxP;Padi2/ mice were injected with tamoxifen at postnatal day 6 (P6) and sacrificed at P11, and brains and spinal cords were collected.
(D) The number of CC1 and GFP double-positive cells was estimated out of total GFP+ cells in both corpus callosum and spinal cord of PdgfraCreERT;RCE:
loxP;Padi2+/+ and PdgfraCreERT;RCE:loxP;Padi2/ mice. Means ± SEM are shown, n = 5 (control [Ct]) and n = 4 (indKO); *p < 0.05, two-tailed t test.
See also Figure S2.epithelial cells (Cherrington et al., 2010) and has been found to
inhibit transcription through RNA polymerase (Pol) II citrullination
in breast cancer cell line T47D (Sharma et al., 2019). Further-
more, PAD2 was able to citrullinate nuclear histone H3R26 in
MCF-7 breast cancer cells (Zhang et al., 2012). Remarkably,
immunocytochemistry analysis showed the presence of PAD2
protein both in the nucleus and the cytoplasm of differentiated
Oli-neu (Figure 5A) and in primary OPCs (MBP negative) and
OLs (MBP positive) (Figure S2E). In order to confirm the localiza-
tion of PAD2 in the nucleus of OPCs, we transfected Oli-neu cells
with the fusion vector Padi2-ZsGreen. We observed the pres-
ence of the green fusion protein both in the nucleus and cyto-
plasm of these cells (Figure 5B), indicating that PAD2 can indeed
be nuclear in OL lineage cells and might thereby regulate tran-
scription through epigenetic mechanisms.
PAD2 Citrullinates Nuclear Proteins
To determine what could be the molecular targets of PAD2 in
both nuclei and cytoplasm, we generated a stable Padi2-overex-1094 Cell Reports 27, 1090–1102, April 23, 2019pressing Oli-neu cell line, in which citrullination activity was
greatly enhanced when tested in an antibody-based assay for
PAD activity (ABAP) (Zendman et al., 2007) (Figure 7C) and per-
formed quantitative proteomics by applying stable isotope label-
ing of amino acids in cell culture (SILAC) followed by mass spec-
trometry (Ong et al., 2002). SILAC relies on the incorporation of a
light (12C) or a heavy (13C) isotopic version of lysine into proteins
of control and overexpressing Padi2 cell lines, respectively. The
proteomes of fully light (L) and heavily (H) labeled cells were
mixed 1:1, and the relative dissimilarities in the proteome citrulli-
nation target sites of these cell populations were determined and
quantified usingmass spectrometry (Figure 5C; STARMethods).
Interestingly, we observed a striking difference in the number of
citrullination targets and ratios between proliferating and differ-
entiating Oli-neu cells (Figure 5D). In the proteome of prolifer-
ating Oli-neu, we found up to 151 citrullination sites, of which
81 were upregulated (H/L SILAC ratio higher than 1.5) with
Padi2 overexpression. In contrast, up to 500 citrullination sites
were identified in differentiating Oli-neu cells, of which 347
Figure 4. Padi2 Conditional and Full Knockout Mice Exhibit Impaired Motor and Cognitive Functions and Decreased Myelinated Axons
(A–C) Behavior tests for motor (rotarod [A] and beam test [B]) and cognitive (novel object recognition [C]) performance in controls (PdgfraCre;RCE:loxP;Padi2+/+
and wild-type [WT]), Padi2 heterozygous (Padi2 het), and Padi2 full knockout (fKO) and conditional KO (Padi2 cKO; PdgfraCre;RCE:loxP;Padi2/). For the
rotarod test, the time spent on rotating rod, latency to fall, was measured in seconds, and for the novel object recognition, test the discrimination index
corresponds to percentage ratio between the time exploring the novel object and the total time spent exploring both objects. Means ± SEM are shown, WT n = 8,
Padi2 het n = 11, Padi2 fKO n = 11 (*p < 0.05, one-way ANOVA), control (Ct) n = 10, and Padi2 cKO n = 10 (*p < 0.05, Mann-Whitney test).
(D) Representative electron microcopy (EM) images for WT and Padi2 fKO corpus callosum. Scale bar, 1 mm.
(E and F) Scatterplot of g-ratio as a function of axon diameter (mm) (F) and graph plot for the g-ratio distribution across different axon diameters (E) inWT (n = 4) and
Padi2fKO (n = 4).
(G) Percentage of myelinated axons present in the corpus callosum of WT and Padi2 fKO. Means ± SEM are shown, n = 4; *p < 0.05, Mann-Whitney test.were upregulated upon Padi2 overexpression (Figure 5D; Table
S1). These observations indicate that OLs have an intracellular
environment that ismore permissive to PAD2 activity thanOPCs.
We also uncovered citrullination sites arising only with Padi2
overexpression (no H/L SILAC ratio with peptides detected
only in heavy proteomes; Figure 5E; Table S1). Consistent with
our previous observations on the localization of PAD2 in theOL lineage (Figures 4A and 4B), PAD2 targets were not only cyto-
plasmic, such as ribosomal proteins and myelin proteins (such
as HSPA8, CNP and RAB1, ENO1 and EEF1A; Jahn et al.,
2009), but also nuclear (Figure 5E; Table S1). Chromatin compo-
nents and modulators such as histone H1 (HIST1H1B), histone
H2b (HIST1H2BA), histone H3 (HIST1H3), the histone demethy-
lase KDM3B, and the chromodomain helicase DNA bindingCell Reports 27, 1090–1102, April 23, 2019 1095
Figure 5. Padi2 Overexpression Unveils Citrullination Targets
(A) Immunocytochemistry in 2 day differentiated Oli-neu for PAD2 (yellow) and CNPase (magenta) depicting PAD2 in the nucleus and cytoplasm of cells. Scale
bar, 20 mm.
(B) Transfection of Oli-neu cells with Padi2 fused with ZsGreen (depicted in yellow) shows the PAD2-ZsGreen both in the cytoplasm and in the nucleus. Scale
bar, 20 mm.
(C) Schematic representation of the strategy used to determine the citrullination targets by means of SILAC followed by mass spectrometry. Control and
overexpressing Padi2 cell lines are fed with 12C (light) and 13C (heavy) media, respectively. Proteins from proliferating and 2 days differentiating cells are collected
from both light and heavy media and mixed 1:1 for further mass spectrometry analysis.
(D) Boxplot representing the fold change of the identified citrullination targets in Oli-neu cells in both proliferation and differentiation conditions. Ratios are
represented as log2(H/L ratio), and PAD2-mediated citrullination targets were considered above a threshold of 1 (dashed line).
(E) Table representing top citrullination targets of PAD2 in proliferation and differentiation conditions.N represents proteins for which only peptides with heavy
labeling were detected.
(F) GeneOntology (GO) analysis for biological processes on the PAD2citrullinated proteins. Themost significant categories (±log10[false discovery rate]) were plotted.
See also Figure S2 and Tables S1 and S4.protein 6 (CHD6), among others, were identified to be citrulli-
nated by PAD2 at specific arginines (Figure 5E). We also
observed citrullination of several RNA binding proteins, consis-
tent with the abundance or arginines in their RNA binding motifs
(Figure 5F). Gene Ontology (GO) analysis indicated that proteins
citrullinated by PAD2 are involved in translation, ribosomal
biogenesis, and nucleosome assembly in both proliferating and
differentiating conditions and RNA splicing, RNA processing,
and posttranscriptional regulation of gene expression in differen-1096 Cell Reports 27, 1090–1102, April 23, 2019tiating conditions (Figure 5F; Table S4). Thus, PAD2 activity is not
circumscribed to myelin and cytoplasmic proteins but is also
relevant to nuclear processes.
PAD2Protein-Protein InteractionNetwork Is Enriched in
Cytoplasmic and Myelin Proteins
Our data suggest that PAD2 might be involved in different biolog-
ical cell processes occurring both in the nucleus and in the cyto-
plasm. To further explore the PAD2 role in OL lineage cells, we
Figure 6. PAD2 Protein Interactors in Oli-neu Cells
(A) Schematic representation of the strategy used to uncover PAD2-interacting proteins by means of SILAC followed by mass spectrometry. Control cells
(expressing biotin ligase BirA and empty vector) and biotin-tagged Padi2 (bioPadi2) cell lines (expressing BirA and the biotin-tagged Padi2) are fed with 12C (light)
and 13C (heavy) media, respectively. Immunoprecipitation (IP) with streptavidin beads is performed on the same amount of proteins collected from control or
bioPadi2 cells. After IP, the streptavidin beads from the two conditions are mixed are analyzed using mass spectrometry.
(B) Graph plot representing all detected immunoprecipitated proteins by mass spectrometry in both proliferating and upon 2 days differentiation of Oli-neu cells.
Ratios are represented as log2(H/L ratio) and PAD2-interacting proteins were considered for analysis when displaying a threshold above 1 and detected in both
proliferation and differentiation (all targets in the upright quadrant).
(C) Short list of the top ten PAD2-interacting proteins that were previously shown in the myelin proteome.
(D) GO analysis for biological processes on the PAD2 interacting proteins. The most significant categories (+/ Log10 (false discovery rate)) were plotted.
(E) Network analysis of all PAD2 interactors, proteins found on the cellular component GO analysis for the myelin sheath are highlighted in red.
See also Tables S2 and S4.identified the PAD2 protein interactors by pulling down biotin-
tagged PAD2. Control (expressing biotin ligase, BirA, and empty
vector) and biotin-tagged Padi2 (bioPadi2) Oli-neu cell lines (ex-
pressing BirA and the biotin-tagged Padi2) were fed with 12C or
13C isotopes, respectively, immunoprecipitated with streptavidin
beads, and combined for furthermass spectrometry analysis (Fig-
ure 6A). As expected, PAD2 was the protein enriched the most
(Figure 6B). We uncovered up to 74 shared PAD2 protein interac-
tors in proliferating and 2 days differentiatedOli-neu cells (Figures
6B–6E; Table S2), including nuclear proteins such as elongator
protein complex 1 (ELP1). Nevertheless, the number of interactors
wasmuch smaller than citrullination targets, suggesting thatmost
of the PAD2 interactions leading to citrullination are transient and
cannot be captured. Yet, GO analysis of the biological processes
showed common categorieswith theGOanalysis of the PAD2 cit-
rullination targets, such as translation and posttranscriptional
regulation of gene expression (Figure 6D), suggesting once again
a role for PAD2 in these processes. Interestingly, one of the cate-gories in the GO analysis, the intracellular protein transport, com-
prises RAN and KPNB1, two key regulators for active nuclear
transport, which suggests that these proteins can be involved in
the PAD2 nuclear-cytoplasmic shuttling (Table S2). When per-
forming GO analysis for the cellular component, we also have
identified a myelin sheath component of PAD2 interactors (Fig-
ure 6E, myelin sheath partners highlighted in red; Table S4).
Furthermore, comparison with a previously published myelin pro-
teome (Jahn et al., 2009) uncovers additional myelin proteins that
interact with PAD2, such as WDR1 and FASN, among others
(Figure 6E; Table S2). Thus, although interactions of PAD2 with
nuclear proteins might be more transient, we observed several
myelin proteins interacting with this enzyme.
Histone Citrullination by PAD2 Is Associated with
Regulation of OL Differentiation Genes
Because we found PAD2 in the nucleus of OL lineage cells and
identified several chromatin-associated proteins as targets ofCell Reports 27, 1090–1102, April 23, 2019 1097
Figure 7. PAD2 Citrullinates Histones and Regulates the Expression and Chromatin Accessibility of Genes Involved in OL Differentiation
(A) Western blot for H3R2+8+17cit and H3R26cit upon treatment of proliferating Oli-neu cells with either DMSO or Cl-amidine 200 mM for 2 days. GAPDH signal is
an internal loading control. Images represent n = 2.
(B) Western blot analysis for PAD2, histone H3R2+8+17cit, and H3R26 on Padi2-overexpressing cell line versus control. GAPDH was used as a loading control.
Representative images of n = 3.
(C) Analysis of Oli-neu cell line overexpressing Padi2 or scramble control. Padi2-overexpressing cells display higher PAD activity, as assessed using the ABAP kit
assay, and high mRNA Padi2, as assessed using qRT-PCR. Comparative gene expression gene analysis of proliferating and undifferentiated (Und) Oli-neu cells
and 2 days differentiated Oli-neu cells (Diff) overexpressing Padi2, n = 3 (Mbp, Mog, Sox10, and Sox9). Means ± SEM are shown; *p < 0.05, two-tailed t test.
(D) IGV genomebrowser overlay views depicting chromatin accessibility (assessed using ATAC-seq) near transcription start sites, in Oli-neu cells transfected with
control (Ctrl) siRNAs (blue) and siRNA against Padi2 (red) (n = 3, samples pooled for visualization, same scale for Ctrl siRNA and Padi2 siRNA).
See also Tables S3 and S4.PAD2, we investigated whether citrullinated nuclear proteins,
such as histones, are present in OL lineage cells using an orthog-
onal technique. Indeed,western blot analysis of histone citrullina-
tion showed the presence of histone H3R26Cit and histone
H3R2+8+17Cit in proliferating Oli-neu cells (Figure 7A). Treatment
with 200 mM of the pan PAD inhibitor Cl-amidine or 60 mM of
2-CA led to a reduction on these modifications (Figure 7A). We
also observed increases of histone H3R2+8+17Cit and Histone
H3R26Cit in the Padi2-overexpressing cell lines, indicating that
PAD2 is mediating histone H3 citrullination and thus acts as an
epigenetic regulator in OL lineage cells (Figure 7B). Although
the expression of Mog, Sox10, and Sox9 was not altered upon
Padi2 overexpression, we observed upregulation of Mbp in
differentiating cells (Figure 7C), corroborating their downregula-
tion upon PAD2 inhibition or Padi2 knockdown (Figure 2). Thus,
histone citrullination might be one of the mechanisms by which
PAD2 regulates the transition of OPCs to NFOLs.1098 Cell Reports 27, 1090–1102, April 23, 2019Padi2 Knockdown Results in Reduced Accessibility in
OL Differentiation Genes
To further examine the possible role of PAD2 in transcriptional
regulation and the chromatin structure, we investigated if the
knockdown of Padi2 would affect the chromatin accessibility.
We performed assay for transposase-accessible chromatin
using sequencing (ATAC-seq; Buenrostro et al., 2013) to identify
changes in accessibility of regulatory regions in differentiating
Oli-neu upon knockdown of Padi2with siRNAs (Figure 7D). Inter-
estingly, we observed a general reduction in accessibility upon
knockdown of Padi2 (Figures 7D and S3A; Table S3). We further
investigated accessibility of OL enhancers and promoters,
presenting H3K27ac in Oli-neu cells (see STAR Methods) or
H3K27ac and/or H3K4me3 in OPCs (Lu et al., 2016). Indeed,
we observed decreased chromatin accessibility in regulatory
regions of genes such as Pik3cd, Plin4, and Ezh1. Importantly,
we also observed such reduction in accessibility in important
regulators of OLmyelination, including Sirt2,Mag, andMbp (Fig-
ure 7D) and in Plp1, Sox10, andMog, although to a minor extent
(Figure S3A). Accordingly, GO analysis indicated an enrichment
in regulatory regions of genes involved in lipid metabolism (Fig-
ure S3B; Table S4). Nevertheless, PAD2 appears to target spe-
cific regulatory regions, because we did not find regulation of
chromatin accessibility at regulatory regions of other genes
modulating OL differentiation, such as Sox9, Tcf7l2 (Figure 7D),
Id1, and Olig2 (Figure S3A). Interestingly, we also find a cohort
of genes in which accessibility of their regulatory regions was
instead increased by Padi2 knockdown, including Cxcl2 (Fig-
ure 7D), Hspb8, and Gabra6 (Figure S3A). GO analysis indicated
involvement in the processes of chemotaxis, Polycomb activity,
and apoptosis, among others (Figure S3B; Table S4). As such,
recruitment of PAD2 to specific regulatory regions in OLs regu-
lates their accessibility, which will also ultimately modulate tran-
scriptional output, as observed for Mog, Mbp, and Sox10.
DISCUSSION
The formation of myelin is a fundamental biological process that
encompasses subsequent steps of OPC specification, differen-
tiation, and myelin sheath formation and wrapping of axons. Our
study highlights PAD2 as an important player in these last two
steps by (1) facilitating OPC differentiation and influencing the
OL epigenetic landscape through histone citrullination and (2) in-
teracting with and mediating the citrullination of several myelin
protein components. Although Padi2 expression in OLs and its
occurrence in myelin were described before (Wood et al.,
2008), we report its presence in OPCs and the dramatic upregu-
lation of Padi2 in the transition from OPCs to NFOLs and its
function facilitating OL lineage progression. To uncover PAD2
mechanisms of action, we further determined the citrullination
targets and the binding partners of PAD2. Our data revealed pro-
teins citrullinated by and interacting with PAD2, both located in
the nuclear and cytoplasmic compartments. We also demon-
strate, using different Padi2 KOmouse lines, that PAD2 is impor-
tant for OL development and motoric and cognitive behavior.
Our findings indicate that PAD2-mediated citrullination is
required for efficient OL development, not only acting as amyelin
modulator, through MBP citrullination, but also displaying other
functions in the cytoplasm and nucleus, for instance as an epige-
netic modulator. Additional mechanisms underlying PAD2 ac-
tions in OPC differentiation remain to be investigated.
Using an unbiased proteomics methodology based on SILAC
followed by mass spectrometry, we revealed hundreds of citrul-
lination protein targets and the respective arginine locations,
some of those in core histones such as HIST1H1, HIST1H2,
and HIST1H3. PAD2-mediated H3R26Cit has been shown to
lead to local chromatin decondensation and targeted transcrip-
tional activation in breast cancer cells (Guertin et al., 2014). In a
similar manner, when we knocked down Padi2, we observed a
general decrease in chromatin accessibility, as revealed by
ATAC-seq. Furthermore, upon PAD inhibition or Padi2 knock-
down, we observed a decrease in the pro-differentiation and
myelin genes such as Mbp, Mog, and Sox10, suggesting that
PAD2 might be locally enhancing transcription through histone
H3 citrullination.Interestingly, we detected HIST1H1C citrullination on arginine
(R) R54 in our cells. This modification was previously described
to induce global chromatin decondensation in induced pluripo-
tent stem (iPS) cells (Christophorou et al., 2014) and to be specif-
ically mediated by PAD4, which suggests that there is an overlap
of the substrates of PAD2 and PAD4. Moreover, H3R2+8+17Cit
was also induced upon hPadi4 overexpression (Christophorou
et al., 2014). hPAD2 and hPAD4 were shown to exhibit different
substrate preferences and hPAD4 had more pronounced sub-
strate specificity, in both Cos-1 and HEK cells or by adding re-
combinant hPADs to cell lysates (Assohou-Luty et al., 2014).
Additional hPAD2 targets were disclosed by overexpressing
hPAD2 in HEK cells using a different technology (Lewallen et al.,
2015). Although these are targets for hPAD2 in different human
cell types, we observed many common targets with our mouse
OL lineage cells, such as ribosomal proteins and splicing factors.
Thus, PAD2 might have a widespread and undetermined role in
basic cellular processes such as mRNA splicing and translation.
Differentiated Oli-neu cells displayed considerably more
citrullination targets, higher citrullination activity in basal condi-
tions with the ABAP kit, and a more pronounced increase in
H3R2+8+17Cit and H3R26Cit upon Padi2 overexpression, sug-
gesting that PAD2 activity can be enhanced upon differentiation.
In agreement, most of PAD2 effects are more noticeable upon
OPC differentiation. Of note, PAD activity can also be context
dependent, as these enzymes need a high concentration of cal-
cium to become active, and calcium signaling has been shown to
be fundamental for OPC migration, differentiation, and myelina-
tion (Pitman and Young, 2016). Although several citrullination
targets found in proliferating and 2 days differentiated Oli-neu
were common and/or showed additional citrullinated arginine
in differentiation, they did not overlap completely, indicating
that there is a preference for the targeted arginine between these
conditions that could be due, for instance, to differences in bind-
ing partners. Likewise, not all proteins found to interact with
PAD2 were citrullinated, and vice versa. Nevertheless, GO anal-
ysis for the biological processes on the PAD2 interactors also
revealed categories similar to the citrullination targets, such as
translation and posttranscriptional regulation of gene expres-
sion, reinforcing once again a putative role for PAD2 in these
processes.
Mice overexpressing Padi2 under the Mbp promoter display
abnormal myelination with structural changes of the myelin
(Musse et al., 2008). This effect was attributed to the increased
citrullination of MBP and also of histones that would ultimately
cause OL apoptosis (Musse et al., 2008). However, a striking
finding in our study is the abundance of myelin component pro-
teins within the interactors of PAD2, which might also mediate
the effect of PAD2 on myelin when overexpressed (Musse
et al., 2008). Citrullination of myelin proteins is naturally occur-
ring, and thus normal citrullination levels must certainly have a
physiological function. 20,30-Cyclic-nucleotide 30-phosphodies-
terase (CNPase), which has an important role in the generation
of cytoplasmic channels in OLs (Snaidero et al., 2017), displayed
PAD2-mediated citrullination of several arginines (Table S1). It is
possible that hypocitrullination of CNPase upon knocking out
PAD2 could lead to disruption of cytoplasmic channels and ulti-
mately to the observed defects on myelination in our Padi2 fKOCell Reports 27, 1090–1102, April 23, 2019 1099
mice (Figure 7). Further investigation would be necessary to
determine which citrullination targets of PAD2 in themyelin could
be responsible for these defects.
We found that PAD2 absence in OL lineage cells caused
decreased OL cell density in the spinal cord in juvenile mouse
and a decrease in the number of myelinated axons in the
corpus callosum of adult mice that were reflected in motor and
cognitive dysfunctions. Because Pdgfra and Padi2 can also be
co-expressed in other non-CNS cells, such as Schwann cells,
the impairment on motor functions could also be due to the
absence of PAD2 in peripheral cells. However, overexpression
of Padi2 did not have any effect on the peripheral myelin (Musse
et al., 2008), and the electron microcopy and OL density analysis
in the brain and spinal cord (Figure 7) indicated a phenotype in
OLs. In addition, the cognitive behavior test also supports a
CNS-specific PAD2 effect.
Analysis of single-cell RNA-seq data (Figure S1) suggested
that PAD2 is the only member of the PAD family robustly ex-
pressed in the OL lineage. Although PAD4 was identified by
immunohistochemistry in the myelin (Wood et al., 2008), we
could not detect Padi4 mRNA in any OL lineage cell tested, nor
it was identified in the myelin proteome (Jahn et al., 2009). How-
ever, we did detect very low mRNA levels of Padi3 and Padi1 in
Oli-neu cells and found it expressed in very few cells in OPCs or
OLs collected from P90 brains (data not shown). As such, we
cannot rule out that these PADs have a function in OL lineage
progression and that compensatory mechanismsmight be oper-
ational upon PAD2 knockdown, KO, or inhibition, particularly as
PADs can have overlapping substrates.
PAD2 has been long investigated in the context ofMSbecause
MBP hypercitrullination is a hallmark of the disease (Yang et al.,
2016). Our study demonstrates that PAD2-mediated citrullina-
tion is also required for OL lineage progression and myelination
and uncovers several citrullination targets in the OL lineage.
Thus, targeted activation of PAD2 in the OL lineage might be
beneficial in the context of remyelination in diseases as MS.STAR+METHODS
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pCAG-Padi2-Hygro This paper N/A
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This paper N/A
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Primers for genotyping, see Table S5 This paper N/A
Primers for qPCR, see Table S5 This paper N/A
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ECLTMPrime Western Blotting Detection Reagent GE Heathcare RPN2236
Supersignal west femto ThermoFisher Scientific 34095
Streptavidin beads, DB Myone Streptavidin T1 Invitrogen, ThermosFisher Scientific 65601
Protease Inhibitors Sigma 11873580001
Phenol:Chloroform:Isoamyl (25:24:1) Invitrogen, ThermosFisher Scientific 15593031
Nextera Tn5 Transposase Illumina #FC-121-1030
Deposited data
ChIP seq This work GEO: GSE115929
Software and algorithms
Cytoscape Shannon et al., 2003 http://www.cytoscape.org/; RRID:SCR_003032
Cell profiler Broad Institute, Cambridge, MA RRID:SCR_007358
GraphPad Prism 6 www.graphpad.com www.graphpad.com; RRID:SCR_002798
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Further information and requests for resources and reagents should be directed to and will be fulfilled by the Lead Contact, Goncalo
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EXPERIMENTAL MODELS AND SUBJECT DETAILS
Transgenic Mice Strains
All mice were maintained under a pathogen-free environment at the animal facility. Animals were used in adult stage, between
10-12 weeks old and both genders were included. The following light/dark cycle was used: dawn 6.00-7.00; daylight 07.00-18.00;
dusk 18-00-19.00; night 19.00-06.00. A maximum of 5 adult mice per IVC-cage of type II Allentown. Breedings were done with 1
male and up to 2 females. All experimental procedures were performed following the guidelines and recommendations of local animal
protection legislation and were approved by the local committee for ethical experiments on laboratory animals (Stockholms Norra
Djurfo¨rso¨ksetiska na¨mnd in Sweden). The following transgenic mice strains were used:
Pdgfra-H2BGFP knock-in mice(Klinghoffer et al., 2002) where H2B-eGFP fusion gene is expressed under the promoter of Pdgfra.
Pdgfra-H2BGFP pups of both genders from postnatal day P1 to P4 were used for primary cultures.
Pdgfra-Cre BAC transgenic mice (The Jackson Laboratories, CA, USA), where Cre recombinase is under the control of the Pdgfra
promoter;
RCE:loxP, an EGFP reporter mice (Gord Fishell, NYU Neuroscience Institute);
Pdgfra-CreERT BAC transgenic mice (The Jackson Laboratories, CA, USA)
Padi2tm1a(KOMP)Wtsi (UCDAVIS KOMP Repository Knockout Mouse Project)
Actb:FLPe (The Jackson Laboratories, CA, USA).
All individual mice strains were in a C57BL/6NJ genetic background, at the exception of RCE:loxP-GFP that was in a CD1 back-
ground.
Padi2fl/fl was generated by breeding Padi2tm1a(KOMP)Wtsi with Flp deleter mice. Padi2fl/fl mice were crossed with RCE:loxP, Pdgfra-
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PdgfraCre; RCE:loxP and PdgfraCre; RCE:loxP; Padi2 mouse lines were used for qPCR analysis at several ages (postnatal P1-P4,
juvenile P21 and adult P60) with both genders included. Behavioral analysis of PdgfraCre; RCE:loxP; Padi2 was performed in 4month
adult and both genders were included. Immunohistochemistry analysis was performed in both juvenile P21 (both genders included)
and 4-month old adults (only females).
Tamoxifen (Sigma T5648) was dissolved in corn oil and administrated i.p. in P6 Pdgfra-CreERT;RCE:loxP;Padi2fl/fl pups at a dose
of 2mg/40 g. Brain and spinal cord were subsequently collected at P11. Genders were not confidently determined at this age in these
pups.
Use of full PAD2 KO mice was strictly compliant with the guidelines set forth by the US Public Health Service in their policy on
Human Care and Use of Laboratory Animals, and in the Guide for the Care and Use of Laboratory Animals. Mice were maintained
under a pathogen-free environment at the animal facility of Mount Sinai Medical Center. All procedures received prior approval
from the Institutional Animal Care and Use Committee (IACUC). The C57BL/6-PAD2-KO mice were obtained from the Scripps
Research Institute (Kerri Mowen’s laboratory) which was originally from Lexicon Genetics (Woodlands, TX). Behavioral analysis
was performed in 4 month old mice, both genders were included. EM analysis comprised 7 month old males.
Cell Lines
Oli-neu + Padi2_Zc_Green, Oli-neu + pB-CAG-Ctr + PBase, Oli-neu + pB-CAG-Padi2 + PBase, Oli-neu + pB-CAG-BirA + PB-CAG-
IRES-GFP + pBase and Oli-neu + pB-CAG-BirA + pB-CAG-bioPadi2-IRES-GFP + PBase were all generated in this paper from
Oli-neu cell lines donated by Jacqueline Trotter, Johannes Gutenberg University, Germany.
METHODS DETAILS
Genotyping of Padi2fl/fl Mice
We have assessed the presence of the floxed cassette and the product of the Cre/CreERT mediated DNA deletion (Figure S2A) by
performing genotyping in mouse ear or tail DNA. Mouse ear and tail DNA have Pdgfra positive and negative cells and therefore
allowed us to classify mice asWT, hetero or homozygous for the floxed cassette but also for the presence or absence of a PCR prod-
uct band that occurs only when Cre/CreERT is active (post-cre band). We also confirmed the disruption of Padi2 mRNA, at P4 and
P21, by qPCR in Figure S2B.
DNA was extracted by incubating biopsies at 98C for 1h in 75ul of NaOH25mM/EDTA 0.2mM. The reaction was neutralized by
adding 75ul of TrisHCl 40mM pH5.5. After centrifugation for 4min at 4000rpm 2 mL were collected and used in PCR reaction using
DreamTaq Green PCR Master Mix 2x (Thermo Scientific K1081) following manufacturer’s instructions. Primers:
Padi2-F:AGTTAGAGGCCAACTGTGTGAGACC
Padi2-ttR: CCAGAAAGGACCCACATTCAAGAGC
Padi2-R: AGACTCTGTGCTGACATTCTCAGGG
Behavioral Analysis
For the beam balance test the finemotor coordination and balance was assessed by beamwalking assay. Performance on the beam
was quantified by measuring the time taken by the mouse to traverse the beam and the number of paw slips that occurred in the
process. The beam apparatus consisted of a PVC plastic beam (1.2 cm wide 3 100 cm long) located 50 cm above the table top
on two poles. A black box was placed at the end of the beam as the finish point. Nesting material and feces from home cages
was placed in the black box to attract the mouse to the finish point. A nylon or cotton pad was placed below the beam, to cushion
any falls. Mice were trained three times a day for two consecutive days until they were able to cross the beam without hesitation. No
data were collected during these sessions. During the test session, the time needed to cross the beam and the number of paw slips
were recorded. The beam and boxwere cleaned of mouse droppings andwiped with 70%ethanol before the next animal was placed
on the apparatus.
The novel object recognition task was conducted as described previously (Fortress et al., 2013), and was used to assess the non-
spatial hippocampal memory. A mouse was presented with two similar objects during the first session, and then one of the two
objects was replaced by a new object during a second session. The amount of time taken to explore the new object provided the
index of recognition memory. The task consisted of habituation, training, and testing phases conducted on separate days. During
habituation, mice were allowed to freely explore an empty white box (60 cm wide 3 60 cm long 3 47 cm high) for 5 min/day for
two days. Twenty-four hours later, mice were re-habituated (familiarization session) in the same box for 10 min, with two identical
objects placed inside, 5 cm away from the walls. Mice were allowed to freely investigate until they accumulated a total of 20 s
exploring the objects. Exploration and recognition of the object were determined when the nose of the animal was in contact with
an object or directing nose to the object within a defined distance (< 2 cm). Mice were then immediately returned to their home
cage. After the familiarization session, the objects and the open field was cleaned with 70% ethanol to minimize olfactory cues. After
1 hour of familiarization session, object recognition was tested, using the same procedure as in training except that one of the familiar
objects was substituted with a novel object (cleaned and free of olfactory cues). The position of the novel object (left or right) has to be
randomized between each mouse and each group tested. Time spent with each object was recorded using a stopwatch by a trainede4 Cell Reports 27, 1090–1102.e1–e10, April 23, 2019
observer. Mice inherently prefer to explore novel objects; thus, a preference for the novel object indicates intact memory for the
familiar object. A discrimination index was calculated according to the following formula: time of novel object exploration/time of
novel plus familiar object exploration 3 100.
Rotarod behavioral analysis was performed for evaluation of coordination andmotor learning.Mice were trained on a Rotarod (Ugo
Basile, Comerio VA, Italy) at a constant speed (4 rpm), 120 s per day for 3 consecutive days. Subsequently, test day consisted of three
trials on an accelerating rotarod for up to 300 s (starting at 4 rpm accelerating to a final speed of 40 rpm), with mice returned to their
home cages for at least 30 min between trials. The time at which each animal fell from the rod was recorded as a measure of motor
coordination and repeated-measurements of speed at the time of animal falling were averaged.
Electron Microscopy
For EM analysis, deeply anesthetized C57BL/6-PAD2-KO mice (n = 4 per condition) were perfused transcardially using a varistaltic
pump (Manostat) with 0.1M PBS (pH 7.4) followed by cold Karnovsky’s fixative (2.0% PFA/2.5% Glutaraldehyde in 0.1M Sodium
Phosphate buffer).
Using a McIlwain tissue chopper, coronal brain sections between 2.2 and 2.5 bregma were obtained and corpus callosum
tissuewasmicro-dissected and post-fixed overnight in 2.0%PFA/ 2.5%Glutaraldehyde in 0.1MSodiumPhosphate buffer. The sam-
ples were then processed using standard protocols employed by the Stony Brook University Microscopy Core (see below, and
Menezes et al. [2014] andRelucio et al. [2009]). The following day (after overnight post-fixation), an additional fixation stepwas carried
out using 2%osmium tetroxide in 0.1MPBS (pH 7.4), after which samples were dehydrated in a graded series of ethyl alcohol. Finally,
samples were embedded using Durcupan resin in between two pieces of ACLAR sheets (Electron Microscopy Sciences). Ultrathin
sections of 80nm were obtained using a Lecia EM UC7 ultramicrotome and placed on formvar coated slot copper grids (Electron
Microscopy Sciences). Uranyl acetate and lead citrate counterstained samples were viewed under a FEI Tecnai12 BioTwinG2 elec-
tron microscope. Digital images (minimum 10 per animal, taken at 11,000x) were acquired using an AMT XR-60 CCD Digital Camera
system and compiled using Abobe Photoshop software.
G-ratio was determined by dividing the mean axon diameter without myelin by the same axon diameter with myelin. A minimum
of 100 healthy axons were considered per animal. To determine the size distribution of myelinated fibers in corpus callosum,
diameters of all measured axons were separated into four ranges (0.3-0.6, 0.6-0.9, 0.9-1.2, and >1.2 mm). No axons with diameters
smaller than 0.3 mm were considered. Data are expressed as comparison of means between the control and knock-out for each
range. Percentage of myelinated axons was determined by placing a centered grid over the image using ImageJ software, and
counting whether the axon at each intersection wasmyelinated or not. Each data point in the graph corresponds to the percentage
of myelinated/unmyelinated axons, quantified from 4 animals per each condition (4 wild-type and 4 PAD2 mutant mice).
Quantification has been performed by counting at least 100 axons per image, for a total of 10 images per animal. All measurements
were acquired on electron microscopy sections images using an ImageJ software. Unpaired t test were performed to assess
statistical differences between control and knock out mice for both differences in g-ratio per axon diameter range and percent
myelinated axons.
Tissue Dissociation
Cells were isolated from postnatal, juvenile, and adult brains from PdgfraCre;RCE:loxP mice, and from juvenile brains from Pdgfra-
Cre;RCE:loxP;Padi2+/+ and PdgfraCre;RCE:loxP;Padi2-/- mice with Neural (for postnatal) and Adult (for juvenile and adult) Tissue
Dissociation kits (P) (Miltenyi Biotec). Cell suspensions were then filtered with 30 mm filter (Partec) and FACS sorted for selection
of GFP+. FACS sorted cells were collected in Eppendorf tubes, centrifuged at 400xg, resuspended in Qiazol and frozen for further
RNA extraction/cDNA synthesis.
FACS
GFP+ cells were FACS sorted using a BD FACSAria III Cell Sorter B5/R3/V3 system. Cells were collected either in PBS for further RNA
extraction processing or in OPCmedia directly into coated plates. For OPC removal onOL lineage cells from juvenile and adult brains,
CD140a (anti-mouse CD140 APC conjugated, BD Bioscience) labeling was performed in tissue-isolated cells and GFP+CD140a+
cells were excluded. To define the gates for specific CD140a+ cells we have performed an additional labeling with APC conjugated
IgG (BD Bioscience) as a negative control.
Cell Culture
Primary OPC Culture
GFP+ OPCs were obtained with FACS from P1-P4 brains (mixed genders) from the Pdgfra-H2BGFP mouse line. The mouse brains
were removed and dissociated in single cell suspensions using the Neural Tissue Dissociation Kit (P) (Miltenyi Biotec, 130-092-628)
according to themanufacturer’s protocol. Cells were seeded in poly-L-lysine (O/N) (Sigma P4707) plus fibronectin (1h) (Sigma F1141)
coated dishes and grown in proliferationmedia comprising DMEM/Gmax (life tec 10565018), N2media (life tec 17502048), Pen/Strep
(life tec 15140122), NeuroBrew (Miltenyi 130-093-566), bFGF 20ng/ml (Peprotech 100-18B) and PDGF-AA 10ng/ml (R&D 520-BB-
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Oli-neu Cell Culture
Oli-neu cells were grown in poly-L-lysine coated dishes and expanded in proliferation media consisting of DMEM ((life tec 41965062),
N2 supplement, Pen/Strep Glu (life tec 10378016), T3 (sigma T6397) 340ng/ml, L-thyroxine (sigma 89430) 400 ng/ml, bFGF 10ng/ml
and Pdgf-BB 1ng/ml. For Oli-neu differentiation, media without growth factors was added for two days in vitro and in the presence of
1 mM of erb inhibitor (PD174265, St Cruz, ref sc-204170).
Rat OPC Cultures
Primary rat OPCs were isolated as reported previously (Liu et al., 2015). Briefly, mixed glia cultures were first derived from rat brain
cortex at postnatal day 1. OPCs were selected by the A2B5 antibody followed by purification with the magnetic rat anti-mouse IgM
beads (Miltenyi Biotec). Purified OPCs were cultured in the SATO medium supplemented with PDGFA and bFGF, and were induced
to differentiate with T3 replacing the growth factors.
Padi inhibition: Oli-neu cells were treated either with ClAmidine (Millipore 506282 and Cayman Chem 10599) or 2-chloroaceta-
midine (2CA) (Sigma C0267) at a concentration of 200 mM and 60 mM for one and two days, respectively, in proliferation and differ-
entiation media.
SILAC
To generate LIGHT andHEAVY labeled cell lines, Oli-neu cells were grown and expanded in LIGHT (Lysine 12C) or HEAVY (Lysine 13C)
media for at least five passages. The media was prepared with SILAC Advanced DMEM/F12-FLEX kit (Life Tec, MS10033) and con-
tained 0.1% of dialyzed FBS, 10ng/ml bFGF, 10ng/ml PDGF-BB, 400ng/ml of L-thyroxine and 340ng/ml of T3. For the differentiation,
growth factors and the FBS were removed.
LIGHT labeled cells lines correspond to all controls, scramble overexpression control and BirA control, while HEAVY labeled cell
lines comprise the overexpression of Padi2 or the biotin-tagged Padi2. A control experiment in which control cells were also fed with
heavy media and then mixed 1:1 with light control cells was performed in order to confirm that all proteins in heavy conditions were
heavily labeled (Figure S2B).
Padi2 Overexpression Cell Lines and Knockdown
Padi2 and Ctr overexpression cell lines were generated by insertion of the following vectors with piggyBac transposon system:
pB-CAG-Ctr, pB-CAG-PADI2 for the control and overexpression of Padi2, respectively; pB-CAG-BirA together with pB-CAG-
IRES-GFP as a control and pB-CAG-BirA together with pB-CAG-bioPadi2-IRES-GFP for the biotin-tagged Padi2. BirA and bioPadi2
cDNA were amplified from the plasmids pEF1aBirAV5-neo and pEF1aFlagbio(FLBIO)-puro (Kim et al., 2009) before inserting in
piggyback plasmids. The gateway system was used to clone all these vectors in the final piggyback plasmids (Gateway LR
Clonase II Enzyme mix, Invitrogen/ThermosFisher Scientific, 11791020 and Gateway BP Clonase II Enzyme mix, Invitrogen/
ThermosFisher Scientific, 11789020). pCAG-IRES-GFPwas generated bymodifying the donor plasmid (pB-CAG-eGFP) by replacing
the eGFP by a IRES-GFP sequence subcloned from the plasmid pCALNL-IRES-GFP). pB-CAG-Ctr, pB-CAG-Padi2, pB-CAG-BirA +
pB-CAG-IRES-GFP and pB-CAG-BirA + pB-CAG-bioPadi2-IRES-GFP were transfected together with piggyBac transposase
(pBase) expression vector by lipofection according to the manufacturer’s instructions (Lipofectamine 2000, Invitrogen
11668019). To select for biotin-tagged Padi2 and pB-CAG-IRES-GFP vectors cells were FAC sorted for GFP, all the other cell lines
express the hygromycin resistance gene in the DNA integrated vectors and were selected and expanded in media containing
200 mgml1 of hygromycin (Hygromycin B gold ant-hg-1, InvivoGen).
For the expression of the fusion Padi2 plasmid in Oli-neu OPCs, Padi2 was cloned into the pZsGreen1-N1 plasmid (Clontech,
632448). Oli-neu and primary mouse OPCs were then transfected with these plasmids with Lipofectamine2000 according to the
manufacturer’s instructions.
For silencingPadi2we used the siDESIGN center fromDharmacon. The following siRNAswere selected and purchased fromDhar-
macon GE Healthcare: mouse Padi2; sense: 50 CGUACGUGAUGGAGAGGCAUU 30; antisense: 50 UGCCUCUCCAUCACGUACGUU
30 and ON-TARGETplus Non-targeting siRNA #1 (D-001810-01-20).
Knockdown experiments for Padi2 were performed both in Oli-neu and mouse primary OPCs with Lipofectamine2000, following
manufacturer’s instructions. For mouse primary OPCs, upon 4h of adding the lipids:DNA complexes to the cells, media was changed
to either proliferation or differentiation and cells were collected two days after. For Oli-neu experiments, upon 4h of adding the lip-
ids:DNA complexes to the cells, media was changed to proliferation for one day and cells were either collected at this point
(proliferation condition) or changed to differentiation media one more day (differentiation condition)
ABAP
Cells were collected in lysis buffer [20mMTris-HCl, pH 7.4; 100mMNaCl; 10mM b-mercaptoethanol; 10%glycerol; protease inhibitor
complete (Roche)] and sonicated for 5 minutes at high power with 30 s on/off cycles at 4C. Then the samples were centrifuged at
13000 x g at 4C for 30 minutes and the supernatant was immediately used for further application. PAD activity was determined with
the Antibody Based Assay for PAD activity (ABAP) kit (Modiquest Research, MQ17.101-96) and performed according to manufac-
turer’s protocol. HRP-conjugated secondary antibody was visualized with a TMB substrate solution [1 mg/ml TMB (Sigma Aldrich);
0.1M sodium acetate, pH 5.2; 0.01% hydrogen peroxide] and the reaction was stopped with sulfuric acid [2M H2SO4]. The absor-
bance at 450 nm was determined with a FLUOstar Omega plate reader (BMG Labtech). Human PAD4 enzyme was used as control
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0.002 mU (minimum deimination) and 2.0 mU (maximum deimination) to create a standard curve to correlate activity to the optical
density measured at 450 nm.
RNA Extraction, cDNA Synthesis, and Quantitative Real-Time PCR (qRT-PCR)
RNA was extracted with the miRNeasy mini kit (QIAGEN, 217004) for the Oli-neu cells or with the miRNeasy micro kit (QIAGEN,
217084) for the primary OPCs and direct tissue isolated cells according to manufacturer’s protocols. Contaminating DNA was
degraded by treatment of the samples with RNase-free DNase (QIAGEN, 79254) in column. 0.35-1mg of RNA from each sample
was reversed transcribed for 1h with the High-Capacity cDNA Reverse Transcription Kit (Applied Biosystems, 4368813) including
RNase inhibitor (Applied Biosystems, N8080119). An RT- control was included for each sample. Both the cDNA and the RT- were
diluted 1:5 in RNase/DNase free water.
qPCR reactions were run on a StepOnePlus System (Applied Biosystems) in duplicate and with reverse transcriptase negative re-
actions to control for genomic DNA. Fast SYBRGreen Master Mix (Applied Biosystems, 4385616) was used according to the man-
ufacturer’s instructions, each PCR reaction had a final volume of 10 mL and 1–2.5 mL of diluted cDNA and RT-. The running conditions
were 20 s at 95C, followed by 40 cycles of 3 s of 95C and 30 s of 60C, then 15 s at 95C, 1 minute at 60C and 15 s at 95C. A
melting curve was obtained for each PCR product after each run, to control for primer dimers and gene-specific peaks. Random
PCR products were also run in a 2%–3% agarose gel to verify the size of the amplicon. Tbp, r18S and Gapdh were run as house-
keeping genes. Relative standard curves were generated for each gene to determine relative expression (CT values are converted
to arbitrary quantities of initial template per sample). Expression levels were then obtained by dividing the quantity by the value of
the geometric mean of the housekeeping genes.
PCR primer sequences used are listed in Table S5.
Immunofluorescence
For immunocytochemistry cells were fixed in 4% formaldehyde for 10 minutes, washed in PBS and incubated overnight at 4C with
the primary antibodies anti-CNP (abcam ab6319, 1:200) anti-MBP (Abcam, ab7349, 1:200), anti-PAD2 (rabbit polyclonal; 12110-1-
AP; ProteinTech; 1:200), anti-cleaved Casp3 (rabbit, cell signaling #9661S; 1:200) in PBS/0.5%Trition/10% normal donkey serum
(Sigma, D9663). Cells were washed with PBS and then incubated for 2 hours with Alexa Fluor-conjugated antibodies (Invitrogen,
Alexa Fluor anti-mouse 488 1:1000 and Alexa Fluor anti-mouse 555 1:1000).
For immunohistochemistry mice were perfused at P11 (for tamoxifen-induced PdgfraCreERT;RCE:loxP/Padi2+/+ and
PdgfraCreERT;RCE:loxP;Padi2/) or at P21 and at 4 months (for Pdgfra-Cre;RCE:loxP;Padi2+/+ and PdgfraCre;RCE:loxP;Padi2/)
with PBS followed by 4% PFA. Brains and spinal cords were dissected and post-fixed with 4% PFA for 1h, at 4C. The tissues were
then cryo-protected with a 30% sucrose solution for 24 hours. The tissues were embedded into OCT (Tissue-Tek) and sectioned
coronally (20 um thickness). Sections were incubated overnight at 4C in the following primary antibodies: GFP (Abcam,
ab13970, chicken 1:2000) and CC1 (anti-APC; Millipore, OP80, Mouse 1:100), GFAP (rabbit Dako, Z0334; 1:500) diluted in PBS/
0.5% Triton/10% normal donkey serum. After washing the section with PBS, secondary Alexa Fluor-conjugated antibodies diluted
in PBS/0.5% Triton/10% normal donkey serum were incubated for 2h at room temperature (Invitrogen, Alexa Fluor anti-chicken
488 1:1000 and Alexa Fluor anti-mouse/goat 555 1:1000). Slides were mounted with mounting medium containing DAPI (Vector,
H-1200) and kept at 4C until further microscopic analysis.
Microscopy and Quantitative Analysis
To estimate the number of OL (CC1+ cells), newly formed/Cre recombined OL (GFP+CC1+) and Cre recombined astrocytes
(GFP+GFAP+), 2-3 sections per animal (at same positions of the anterior-posterior axis) were analyzed. For each section, images
were taken for the entire corpus callosum and dorsal funiculus of the spinal cord using a Zeiss LSM700 Confocal. The total number
of CC1+ cells and GFP+CC1+ or GFP+GFAP+ double positive cells was counted using ImageJ software. The percentage of OL and
astrocytes out of total recombined cells at P11 corpus callosum and spinal cord was calculated by estimating the percentage ratio of
GFP+CC1+ out of total GFP+cells for OLs and GFP+GFAP+ out of total GFP+cells for astrocytes. For the estimation of OL density in
juvenile mice confocal images were averaged in ImageJ using z-projection of themax intensity and then loaded into the open-source
software programCellProfiler (Broad Institute, Cambridge,MA), followed by segmentation of images and identification and relating of
primary (nuclei) and secondary (CC1 stained) objects using otsu and global manual thresholding respectively. The counting of CC1
positive or negative cells was calculated in region of interest (ROI) using custommask included in the pipeline, and normalized to the
area.
Western Blot
Cells were collected in 2x Laemmli buffer [120mMTris-HCl, pH 6.8; 4%SDS; 20%glycerol] and sonicated for 5minutes at high power
with 30 s on/off cycles at 4C to shear genomic DNA. Protein concentrations were determined on nanodrop and concentrations were
equalized with 2x Laemmli buffer. Bromophenol blue (0.1%) and b-mercaptoethanol (10%) were added to the samples and the
samples were boiled at 95C for 5 minutes to denature the protein. Equal volumes were loaded in a SDS-PAGE for protein separation
and transferred (100V for 90’) to a PVDFmembrane (GE-healthcare) activated inmethanol. Themembranes were blocked in blocking
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blocking solution) at 4C, washed 3 times 10 minutes in TBS-T [TBS; 0.1% Tween 20] and incubated with a horseradish peroxidase
(HRP)-conjugated secondary antibody (diluted in blocking solution) for 2 hours at room temperature. Proteins were exposed with
ECL Prime western blotting detection reagent kit (GE healthcare) or Supersignal west femto (Thermo Scientific) at a ChemiDoc
XRS imaging system (Bio-Rad). Primary antibodies were used against PADI2 (rabbit polyclonal; 12110-1-AP; ProteinTech; 1:300;
1:1000 for tissue), GAPDH (rabbit monoclonal; 5174S; Cell Signaling; 1:1000), H3Cit2+8+17 (rabbit polyclonal; ab5103; Abcam;
1:1000), H3Cit26 (rabbit polyclonal; ab19847; Abcam; 1:1000), MBP (Covance, SMI99, 1:1000) and ACTIN (Sigma, AC15, 1:10,
000). Secondary antibodies were used at a dilution of 1:5000, anti-rabbit (A6667; Sigma), anti-mouse (A4416; Sigma).
PAD2 Immunoprecipitation
Proliferating and 2-days differentiated BirA controls and biotin-tagged Padi2 cells were fixed for 8 min at RT in 1% formaldehyde
solution by adding 1/10 volume to cell media of freshly prepared 11% formaldehyde solution (formaldehyde 11%, 0.1M NaCl,
1mMEDTA pH8, 0.5mMEGTA pH8 and 50mMHEPES pH8). Glycine was added (final 0.125M) to quench formaldehyde, rinsed twice
in cold PBS and scrapped for subsequent centrifugation at 4000 g for 10min at 4C. At this point cell pellets can be stored at80C.
Cell pellets were then resuspended in 1mL of lysis buffer (10mMHEPES-KOH pH7.5, 100mMNaCl, 1mMEDTA, 0.5mMEGTA, 0.1%
Na-Deoxycolate, 0.5% Na-lauroylsarcosinate, protease inhibitors) and sonicated. Cell suspension was centrifuged at 14000 g for
10min at 4C to remove the debris. For the immunoprecipitation, protein concentrations were determined in every sample and equal
amounts of protein were used for further streptavidin pull-down. 50 mL of streptavidin beads (DB Myone Streptavidin T1, Invitrogen)
per 5mg of protein were added to the protein suspensions and incubated overnight at 4C. Magnetic stand was used to precipitate
the beads. At this step beads from BirA controls and biotin-tagged Padi2 were combined for the following washes: 4 times in wash
buffer 1 (50mM HEPES pH7.6, 1mM EDTA, 0.1% Na-Deoxycolate), 2 times in wash buffer 2 (50mM HEPES pH7.6) and 2 times in
wash buffer 3 (20 mM ammonium bicarbonate NH4HCO3). The beads can be stored at 80C in this step.
Mass Spectrometry for Citrullination Targets
SDS-PAGE Gel
Extracted proteins were resuspended in Laemmli Sample Buffer, and resolved on a 4%–20% SDS-PAGE. The gel was stained with
Coomassie blue, cut into 20 slices and processed for mass spectrometric analysis using standard in gel procedure (Shevchenko
et al., 2006). Briefly, cysteines were reduced with dithiothreitol (DTT), alkylated using chloroacetamide (CAA), and finally the proteins
were digested overnight with endoproteinase Lys-C and loaded onto C18 StageTips prior to mass spectrometric analysis.
Mass Spectrometric Analysis
All MS experiments were performed on a nanoscale EASY-nLC 1000 UHPLC system (Thermo Fisher Scientific) connected to an
Orbitrap Q-Exactive Plus equipped with a nanoelectrospray source (Thermo Fisher Scientific). Each peptide fraction was eluted
off the StageTip, auto-sampled and separated on a 15 cm analytical column (75 mm inner diameter) in-house packed with 1.9-mm
C18 beads (Reprosil Pur-AQ, Dr. Maisch) using a 75 min gradient ranging from 5% to 40% acetonitrile in 0.5% formic acid at a
flow rate of 250 nl/min. The effluent from the HPLC was directly electrosprayed into the mass spectrometer. The Q Exactive plus
mass spectrometer was operated in data-dependent acquisition mode and all samples were analyzed using previously described
‘sensitive’ acquisition method (Kelstrup et al., 2012). Back-bone fragmentation of eluting peptide species were obtained using
higher-energy collisional dissociation (HCD) which ensured high-mass accuracy on both precursor and fragment ions (Olsen
et al., 2005).
Identification of peptides and proteins by MaxQuant
The data analysis was performed with the MaxQuant software suite (version 1.3.0.5) as described (Cox and Mann, 2008) supported
by Andromeda (www.maxquant.org) as the database search engine for peptide identifications (Weidner et al., 1990). We followed the
step-by-step protocol of the MaxQuant software suite (Cox et al., 2009) to generate MS/MS peak lists that were filtered to contain at
most six peaks per 100 Da interval and searched by Andromeda against a concatenated target/decoy (Elias andGygi, 2007) (forward
and reversed) version of the IPI human database. Protein sequences of common contaminants such as human keratins and prote-
ases used were added to the database. The initial mass tolerance in MSmode was set to 7 ppm andMS/MSmass tolerance was set
to 20 ppm. Cysteine carbamidomethylation was searched as a fixed modification, whereas protein N-acetylation, oxidized methio-
nine, deamidation of Asparagine and Glutamine, and citrullination of Arginines were searched as variable modifications. A maximum
of two mis-cleavages was allowed while we required strict LysC specificity. To minimize false identifications, all top-scoring peptide
assignments made by Mascot were filtered based on previous knowledge of individual peptide mass error. Peptide assignments
were statistically evaluated in a Bayesian model on the basis of sequence length and Andromeda score. We only accepted peptides
and proteins with a false discovery rate of less than 1%, estimated on the basis of the number of accepted reverse hits.
Mass Spectrometry for PAD2 Interactome
LC-MS/MS Sample Preparation
The beads were thawed and resuspended in 100ml 25 mM ammonium bicarbonate. The samples were reduced for 1 hour at room
temperature by addition of 1 mM DTT, followed by alkylation for 10 minutes in the dark with 5 mM iodoacetamide. The reaction was
quenched by the addition of 5 mMDTT. 0.2 mg of Trypsin (sequencing grade modified, Pierce) was added to the samples and diges-
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vial and dried in a SpeedVac and resuspended in 3% acetonitrile, 0.1% formic acid. On third of the original sample was injected for
LC-MS/MS analysis.
LC-ESI-MS/MS Q-Exactive
Online LC-MSwas performed using a Dionex UltiMate 3000 RSLCnano System coupled to aQ-Exactivemass spectrometer (Thermo
Scientific). Samples were trapped on a C18 guard desalting column (Acclaim PepMap 100, 75um x 2 cm, nanoViper, C18, 5 mm,
100 A˚), and separated on a 50 cm long C18 column (Easy spray PepMap RSLC, C18, 2 mm, 100A˚, 75 mmx15cm). The nano-capillary
solvent A was 95%water, 5%DMSO, 0.1% formic acid; and solvent Bwas 5%water,5%DMSO, 95% acetonitrile, 0.1% formic acid.
At a constant flow of 0.25 mLmin1, the curved gradient went from 2%Bup to 40%B in 95min, followed by a steep increase to 100%B
in 5 min.
FTMS master scans with 70,000 resolution (and mass range 300-1700 m/z) were followed by data-dependent MS/MS (35 000
resolution) on the top 5 ions using higher energy collision dissociation (HCD) at 30%–40% normalized collision energy. Precursors
were isolatedwith a 2m/z window. Automatic gain control (AGC) targets were 1e6 forMS1 and 1e5 forMS2.Maximum injection times
were 100ms for MS1 and 150-200ms for MS2. The entire duty cycle lasted 2.5 s. Dynamic exclusion was used with 60 s duration.
Precursors with unassigned charge state or charge state 1 were excluded. An underfill ratio of 1% was used.
Peptide and Protein Identification
The MS raw files were searched using Sequest-Target Decoy PSM Validator under the software platform Proteome Discoverer 1.4
(Thermo Scientific) against a mouse database (Uniprot, downloaded on 140320) and filtered to a 1% FDR cut off.
We used a precursor ion mass tolerance of 10 ppm, and a product ion mass tolerance of 0.02 Da for HCD-FTMS. The algorithm
considered tryptic peptides with maximum 2 missed cleavage; carbamidomethylation (C) as a fixed modification; oxidation (M), and
heavy SILAC labeled lysines (Label 13C(6) / +6.020 Da (K)) as dynamic modifications.
ChIP-Seq
Oli-neu cells were rinsed with cold PBS and cross-linked with 1% formaldehyde (Sigma) for 10 min at room temperature (RT) on a
rotating platform. Fixation was quenchedwith 0.125Mglycine for 5min at RT. Cells were rinsedwith cold PBS containing 1x Protease
Inhibitors (PI, Sigma, 11873580001) and collected spinning at 1500rpm for 5 min at 4C. Pellets were resuspended in swelling buffer
(PIPES 5mM, KCl 85 mM, Igepal-CA630 1%, PI 1x), incubated 15min on ice followed by a centrifugation of 1300 g for 5min. This step
was repeated twice and nuclear pellets were resuspended in lysis buffer (1% SDS, 10 mM EDTA, 50 mM Tris-HCl (pH 8.0) and PI 1x)
and incubated for 10 min on ice followed by chromatin sonication using a BioruptorTM UCD200 (Diagenode), high frequency, 30 s
ON/30 s OFF, for 10 min. Protein A/G coated beads (Invitrogen) were washed and resuspended in ChIP dilution buffer (0.01%
SDS, 1%Triton, 1.2mMEDTA, 16.7mMTrisHCl pH8, 167mMNaCl and PI 1x). 20mg of chromatin per ChIPwas diluted in ChIP dilution
buffer and precleared by incubating with 20ml of pre-washed protein A/G coated beads for 1.5h at 4C on a rotator. Beads were
removed and 2mg of the antibody H3K27ac (Millipore, 17-683) was added to the chromatin and incubated overnight at 4C on a
rotator. Incubate 20ml of beads in 1mg/ml of BSA in PBS overnight at 4C on a rotator. Wash beads in ChIP buffer and add to the
chromatin/ab for 1h at 4C on a rotator. Chromatin/ab/beads were washed 3 times low salt wash buffer (0.1% SDS, 2mM EDTA,
20mM TrisHCl pH8, 1% Triton X-100, 150mM NaCl), once with high salt wash buffer (0.1% SDS, 2mM EDTA, 20mM TrisHCl pH8,
1% Triton X-100, 500mM NaCl), once with LiCl wash buffer (0.25M LiCl, 1% IGEPAL-CA630, 1% deoxycholate, 1mM EDTA,
10mM TrisHCl pH8) and once with TE buffer (10 mM Tris-HCl (pH 7.5), 1mM EDTA). Chromatin was eluted by incubating the beads
with elution buffer (1% SDS, 0.1M NaHCO3) for 15 min at RT. Eluted chromatin was reverse cross-linked by adding 10ng/ml of Pro-
teinase K (Thermo Scientific) and 0.1M NaCl. After 2h incubation at 42C, samples were incubated at 65C O/N. Following morning,
10ng/ml of glycogen (Invitrogen) and 1 volume of Phenol:Chloroform:Isoamyl (25:24:1, Invitrogen, 15593031) were added and solu-
tionsweremixed thoroughly before isolating the DNAwithMaxitract HighDensity Tubes (QIAGEN). 2.5 Volumes of 100%ethanol and
1/10 volume of 3MNaOAc (Sigma) were added to the sample and incubated for 15min at80C. DNAwaswashedwith 70%ethanol
and resuspended in nuclease free water.
ATAC-Seq
ATAC-seq was performed as previously described (Buenrostro et al., 2013) with minor adaptations. Oli-neu cells (differentiated,
siRNA treated as described above) were collected with Accutase solution (Sigma, A6964). 50 000 cells per condition were lysed
in lysis buffer (10 mM Tris-HCl, pH 7.4, 10 mM NaCl, 3 mM MgCl2 and 0.1% IGEPAL CA-630) and centrifuged at 500xg at 4C
for 20 minutes. The cells were then resuspended in tagmentation mix (2.5 mL TD buffer, 2.5 mL Tn5 enzyme, Illumina) and the
DNA was transposed for 30 minutes at 37C, where after the DNA was purified using the QIAGEN MinElute kit. After PCR amplifica-
tion with 7-8 cycles (cycles determined with qPCR) the libraries were sequenced on a HiSeq2500 Illumina sequencer. Three
replicates per condition were performed in different days and different passages. Each replicate had >10 million reads with an
average of 45 million reads per sample.
Bioinformatic Analysis of ChIP-Seq and ATAC-Seq
siPadi2 ATAC-seq processing
ATAC-seq siCtrl and siPadi2 replicates were processed separately following the standard ENCODE pipeline for ATAC-seq samples,
https://www.encodeproject.org/pipelines/ENCPL792NWO/. Adapters were detected and trimmed with cutadapt 1.9.1 (Martin,Cell Reports 27, 1090–1102.e1–e10, April 23, 2019 e9
2011) and aligned to mouse genome (GRCm38/mm10) using Bowtie2 (Langmead et al., 2009), with default parameters. After filtering
mitochondrial DNA, reads properly paired were retained andmultimapped reads, with MAPQ < 30, were removed using SAMtools (Li
et al., 2009). PCR duplicates were removed using MarkDuplicates (Picard - latest version 1.126), http://broadinstitute.github.io/
picard/.
ATAC-seq peaks were called using MACS2 https://github.com/taoliu/MACS/ (Zhang et al., 2008), with parameters -g mm -q
0.05–nomodel–shift 100–extsize 200 -B –broad. To get the consensus promoter/enhancer regions from each of the replicates
we first selected the significant peaks -log10(p value) >1.30103. Using bedtools.2.17 mergeBed, we recovered the consensus
ATAC peak region that included more than one replicate for siCtrl samples and siPadi2 samples. From where we recovered
76021 and 55772 union peaks regions for siCtrl and siPadi2, respectively. For visualization and further analyses, the different repli-
cates were merged using Samtools and tracks were normalized using deeptools bamcoverage, normalized with RPKM.
H3K27ac ChIP-Seq Data
Raw reads weremapped to themouse genome (GRCm38/mm10) with Bowtie 2.1.0 (Langmead et al., 2009). Uniquely mapped reads
(17 and 19.5 million for proliferation and differentiation chromatin samples) were then processed with SAMTools for format conver-
sion and removal of PCR duplicates (Li et al., 2009). Broad peaks corresponding to H3K27ac enrichment were called using MACS
2.0.10, with q-value cutoff at 5*10-2 (Zhang et al., 2008). H3K27ac peaks were filtered against blacklisted genomic regions prone to
artifacts (ENCODE Project Consortium, 2012) with BEDTools (Quinlan and Hall, 2010) and annotated to the nearest Transcription
Start Site with PeakAnalyzer (Salmon-Divon et al., 2010).
Defined Promoter/Enhancer Regions
We recovered the regions around the transcription start site (TSS) from gene annotations, ENSEMBL83. The putative promoter re-
gions were extracted as 3KB upstream the TSS and 100bp downstream the TSS, to recover possible promoter and enhancer
regions. To get more reliable signal we intersected the siCtrl union peaks with peaks from H3K27ac ChIP-seq in Oli-neu cells in dif-
ferentiation and proliferation conditions (see above), ending with 17281 siCtrl/promoter peaks overlapping with H3K27ac peaks. Only
the union peaks (7087 peaks) from siCtrl/H3K27ac overlapping the defined promoter regions were retained, using Bedtools intersect
(Quinlan and Hall, 2010). In order to recover possible enhancer and promoter regions that could be have been excluded from
H3K27ac filtering or due to been more downstream of defined promoter regions, we included in the analysis a known mark of
promoters/enhancers, H3K4me3 in OPC-like cells (GSE80089) (Lu et al., 2016). We recovered the peaks bed file of H3K4me3 control
peaks, GSM2112628, (liftover mm9 to mm10) and with bedtools intersect, we recovered 10428 peaks corresponding to siCtrl/
promoter/enhancer peaks with H3K4me3 peaks regions. The final dataset of peaks included the union of both promoter/enhancer
peaks marked by H3K27ac and/or H3K4me3, with a total of 10897 peaks. The final region was extended 200bp up and downstream
for further calculations.
For the differential accessibility analysis between conditions the merged replicates from both conditions were used with Pyicos
(Althammer et al., 2011) on the final peaks dataset, with parameters pyicoenrich–tmm-norm and default parameters. Including the
z-score associated p value and Benjamini & Hochberg (1995) corrected p value (adj p value or FDR) and the log2 fold change for
candidates selection, with adjust p value < 0.05 significance threshold.
Data were visualized with IGV, http://www.broadinstitute.org/igv.
Gene Ontology Analysis
Gene ontology (GO) enrichment analysis for proteomics data were performed using STRING protein-protein interaction networks
(Szklarczyk et al., 2017), and results adjusted for multiple testing using the Benjamini–Hochberg procedure (FDR).
For theGO analyses in ATAC-seq, the top 300 up genes from siCtrl selected peaks and top 300 genes form siPadi2 selected peaks,
based on log2(RPKM siCtrl / RPKM siPadi2) were selected (adjusted p-val < 0.05). GO and pathway analysis was performed with the
ClueGO (version 2.5.1) (Bindea et al., 2009) plug-in Cytoscape (version 3.5.1) (Smoot et al., 2011) with settings, GOBiological process
(20.11.2017) and REACTOME pathways (20.11.2017), showing only pathways with p-val% 0.05. Default settings were used and a
minimum of 4 genes per cluster were used.
QUANTIFICATION AND STATISTICAL ANALYSIS
Statistical analysis was performed in GraphPad Prism7. A parametric and non-paired t test was used to determine statistically sig-
nificant differences between two groups in qPCR experiments with the exception of the rat primary cultures, where a one sample t
test was performed. One-way ANOVA was used to determine differences between three groups in the behavioral analysis of Padi2
fKO. Mann Whitney tests were performed to compare Ct and Padi2 cKO behavior.
DATA AND SOFTWARE AVAILABILITY
The accession number for all raw data has been deposited in GEO: GSE115929.e10 Cell Reports 27, 1090–1102.e1–e10, April 23, 2019
